

Online Resource Table 3

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III

Program

Philip G. Conaghan¹ · Eduardo Mysler² · Yoshiya Tanaka³ · Barbara Da Silva-Tillmann⁴ · Tim Shaw⁵ · John Liu⁴ · Ryan Ferguson⁴ · Jeffrey V. Enejosa⁴ · Stanley Cohen⁶ · Peter Nash⁷ · William Rigby⁸ · Gerd Burmester⁹

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, UK (ORCID: 0000-0002-3478-5665)

² Organización Médica de Investigación, Buenos Aires, Argentina

³ The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan (ORCID: 0000-0002-0807-7139)

⁴ AbbVie Inc., North Chicago, IL, USA

⁵ AbbVie Ltd, Maidenhead, UK

⁶ Metroplex Clinical Research Center, Dallas, TX, USA (ORCID: 0000-00002-9226-979x)

⁷ Griffith University, Brisbane, Queensland, Australia

⁸ Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA (ORCID: 0000-0002-1382-7299)

⁹ Charité-Universitätsmedizin Berlin, Berlin, Germany (ORCID: 0000-0001-7518-1131)

Corresponding author: Philip Conaghan (p.conaghan@leeds.ac.uk)

Online Resource Table 3 Event rates of herpes zoster for upadacitinib 15 mg once daily by region

| | Total drug exposure (PYs) | Unique patients with herpes zoster | E/100PY (95% CI) |
|-----------------------|----------------------------------|---|-------------------------|
| North America | 1187.4 | 36 | 3.1 (2.2, 4.3) |
| South/Central America | 874.2 | 24 | 3.0 (1.9, 4.4) |
| Eastern Europe | 1638.8 | 36 | 2.3 (1.6, 3.2) |
| Western Europe | 366.5 | 15 | 4.9 (2.9, 7.8) |
| Other | 240.6 | 6 | 3.3 (1.4, 6.6) |
| Asia | 258.3 | 25 | 11.2 (7.5, 16.1) |
| Japan | 130.8 | 14 | 12.2 (7.0, 19.9) |

CI confidence interval, *E/100PY* events per 100 patient-years, *PY* patient-year